SKU: A170

size  
Quantity:
 
Price: make selection(s)
Description

Afatinib is an anilinoquinazoline derivative with a reactive acrylamide group.  It is a tyrosine kinase inhibitor and blocks enzymatically active ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor family members. 

    CAS Number

    850140-72-6

    Molecular Formula

    C24H25ClFN5O3

    Molecular Weight

    485.94

    Mechanism of Action

    Afatinib is an irreversible ErbB-family blocker. The reactive acrylamide group is important as it differentiates Afatinib from other ErbB targeting agents by inhibiting the activity of the kinases found in all members of the ErbB family.

    Storage Conditions

    -20┬░C

Applications

    Cancer Applications

    Deregulation of the ErbB receptor network is a driver in epithelial cancers. Afatinib inhibits ErbB-4 and the proliferation of cancer cell lines driven by multiple ErbB receptor aberrations at concentrations below 100 nM (Solca et al, 2012). Afatinib showed positive results during in vitro assays against a variety of human cancer cell lines, including human epidermoid carcinoma cell line A431, murine NIH-3T3 cells, breast cancer cell line BT-474, and gastric cancer cell line NCI-N87. (Li et al, 2008).

Specifications

    Form

    Powder

    Appearance

    White to off-white powder

    Source

    Synthetic

References

    References

    Li D et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702-4711 PMID 18408761 Solca F et al (2012) Target binding properties and cellular activity of Afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exper. Ther. 343(2): 342-350

Other Items In This Category